Quest Diagnostics Incorporated(DGX)- NYSE
  • Wed, Aug. 17, 1:11 PM
    • Quest Diagnostics (NYSE:DGX) declares $0.40/share quarterly dividend, in line with previous.
    • Forward yield 1.89%
    • Payable Oct. 19; for shareholders of record Oct. 4; ex-div Sept. 30.
    | Wed, Aug. 17, 1:11 PM
  • Thu, Jul. 21, 7:58 AM
    • Quest Diagnostics (DGX) Q2 results: Revenues: $1,906M (-1.0%); Operating Income: $422M (+40.2%); Net Income: $195M (+65.3%); EPS: $1.37 (+69.1%); Non-GAAP EPS: $1.34 (+7.2%); Quick Assets: $283M (+112.8%); CF Ops: $464M (+37.7%).
    • 2016 Guidance: Revenue: $7.47B - 7.54B; GAAP EPS: $4.18 - 4.33; Non-GAAP EPS: $5.02 - 5.17; CF Ops: ~$880M; Adjusted CF Ops: ~$1B; CAPEX: $250M - 300M.
    | Thu, Jul. 21, 7:58 AM
  • Thu, Jul. 21, 6:46 AM
    • Quest Diagnostics (NYSE:DGX): Q2 EPS of $1.34 beats by $0.02.
    • Revenue of $1.91B (-1.0% Y/Y) in-line.
    • Press Release
    | Thu, Jul. 21, 6:46 AM
  • Wed, Jul. 20, 5:30 PM
    | Wed, Jul. 20, 5:30 PM | 13 Comments
  • Fri, Jul. 1, 10:28 AM
    • GlaxoSmithKline (NYSE:GSK) upgraded to Buy from Neutral by Citigroup. Price target is 1800p (14% upside).
    • Alexion Pharmaceuticals (NASDAQ:ALXN) upgraded to Buy from Neutral by Citigroup. Price target is $154 (29% upside).
    • IPG Photonics (NASDAQ:IPGP) upgraded to Buy from Hold by Canaccord Genuity. Price target raised to $90 (13% upside) from $85.
    • Centene (NYSE:CNC) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target raised to $86 (21% upside) from $84.
    • Pacira Pharmaceuticals (NASDAQ:PCRX) downgraded to Hold from Buy by Brean Capital.
    • TESARO (NASDAQ:TSRO) downgraded to Hold from Buy by Jefferies.
    • Esperion Therapeutics (NASDAQ:ESPR) downgraded to Equal Weight from Overweight with a $13 (26% upside) price target (from $28) by Barclays. Downgraded to Neutral from Overweight with a $15 (46% upside) price target (from $50) by JPMorgan. Downgraded to Underperform from Neutral with a $10 (0% upside) price target (from $23) by Credit Suisse.
    • HeartWare International (NASDAQ:HTWR) downgraded to Market Perform from Outperform by Wells Fargo. Downgraded to Neutral from Buy with a $58 (0% upside) price target (from $60) by SunTrust Robinson Humphrey.
    • Regulus Therapeutics (NASDAQ:RGLS) downgraded to Market Perform from Outperform by BMO Capital. Price target lowered to $4 (30% upside) from $16.
    • HealthSouth (NYSE:HLS) downgraded to Underweight from Equal Weight by Barclays. Price target lowered to $42 (8% upside) from $45.
    • SciQuest (NASDAQ:SQI) downgraded to Market Perform from Outperform by Raymond James.
    • Quest Diagnostics (NYSE:DGX) downgraded to from Neutral to Sell by Jyske Bank.
    | Fri, Jul. 1, 10:28 AM | 5 Comments
  • Mon, Jun. 27, 11:16 AM
    | Mon, Jun. 27, 11:16 AM | 83 Comments
  • Thu, May 26, 12:59 PM
    • Quest Diagnostics (DGX -0.6%) launches three new test panels under its Quest Vantage brand. The lab-developed panels employ next-generation sequencing and a proprietary bioinformatics platform to identify genetic mutations associated with inherited risk of 15 cancers. According to the company, ~170K diagnoses are made in the U.S. each year of cancers that result from inherited genetic mutations. The three panels are:
    • MYvantage 34-gene Hereditary Comprehensive Cancer Panel for a broad range of cancers.
    • GIvantage Hereditary Colorectal Cancer Test which detects 13 genes associated with colon and gastric cancers.
    • Qvantage Hereditary Women's Health Cancer Test which detects 14 genes predominately associated with breast, colon, uterine and ovarian cancers.
    • The tests only include genes that meet certain criteria such as a 2x increase in cancer risk, an association with a disease syndrome where cancer may occur and guideline support for genetic counseling.
    • Quest will showcase the new panels at ASCO in Chicago, June 3-7.
    | Thu, May 26, 12:59 PM
  • Mon, May 23, 9:32 AM
    • Quest Diagnostics (NYSE:DGX) initiates a public offering of $500M aggregate principal amount of senior notes. Net proceeds will repay current outstanding debt under its senior unsecured revolving credit facility and its secured receivables credit facility in addition to general corporate purposes.
    | Mon, May 23, 9:32 AM
  • Wed, May 18, 9:08 AM
    • Quest Diagnostics (NYSE:DGX) declares $0.40/share quarterly dividend, in line with previous.
    • Forward yield 2.10%.
    • Payable July 20; for shareholders of record July 6; ex-div July 1.
    | Wed, May 18, 9:08 AM
  • Thu, Apr. 28, 7:42 PM
    • Quest Diagnostics (NYSE:DGX) has received emergency use authorization from the FDA for its Zika virus test.
    • It's the first from a commercial lab provider to get an EUA for testing patients for Zika virus RNA, the company says; the CDC had the only previous tests with FDA authorization.
    • Quest says it will make the test broadly available to physicians (including in Puerto Rico) early in the week of May 2.
    • The test, its Zika Virus RNA Qualitative Real-Time RT-PCR test, was developed by the reference laboratory at its Focus Diagnostics subsidiary.
    • Shares were flat in after-hours trading.
    • Now read Theranos Is Toast, It's Time To Look At The Duopoly Of Diagnostic Testing »
    | Thu, Apr. 28, 7:42 PM | 1 Comment
  • Thu, Apr. 21, 8:51 AM
    • Quest Diagnostics (DGX) Q1 results: Revenues: $1,863M (+1.3%); SG&A: $442M (+5.5%); Operating Income: $257M (+12.7%); Net Income: $102M (+67.2%); EPS: $0.70 (+66.7%); Non-GAAP EPS: $1.12 (+6.7%); Quick Assets: $128M (-3.8%).
    • 2016 Guidance: Revenue: $7.52B - 7.59B; non-GAAP EPS: $5.02 - 5.17; CF Ops: ~$1B; CAPEX: $250M - 300M.
    | Thu, Apr. 21, 8:51 AM
  • Thu, Apr. 21, 6:47 AM
    • Quest Diagnostics (NYSE:DGX): Q1 EPS of $1.12 in-line.
    • Revenue of $1.86B (+1.1% Y/Y) beats by $40M.
    • Press Release
    | Thu, Apr. 21, 6:47 AM
  • Wed, Apr. 20, 5:30 PM
    | Wed, Apr. 20, 5:30 PM | 13 Comments
  • Wed, Mar. 30, 8:04 AM
    • Italian firm DiaSorin S.p.A. (OTCPK:DASOY) acquires Quest Diagnostics' (NYSE:DGX) molecular diagnostics and immunoassay products business for $300M in cash. The business, Focus Diagnostics, includes the Simplexa molecular product line, HerpeSelect HSV serology and DxSelect IFA and ELISA assays. The deal should close in Q2.
    • Focus's customer base of large U.S. hospitals will enable DiaSorin to accelerate the penetration of its LIASON immunoassay platform.
    • DiaSorin will continue to manufacture Focus products from its base in Cypress, CA.
    • The transaction does not include Quest's diagnostic information service laboratories currently operating under the Focus Diagnostics brand. The labs, serving hospital and biopharmaceutical firms, will remain a part of Quest and will continue to be based in San Juan Capistrano, CA.
    | Wed, Mar. 30, 8:04 AM
  • Mon, Mar. 28, 5:39 PM
    • Upstart clinical diagnostics firm Theranos gets yet another black eye about its operations. In a study conducted by scientists at the Icahn School of Medicine at Mount Sinai Hospital in New York, blood samples from 60 healthy adults were sent to Theranos, LabCorp (NYSE:LH) and Quest Diagnostics (NYSE:DGX) to compare the accuracy of 22 common tests. The results generated by LH and DGX were from samples obtained via traditional needle-based phlebotomy.
    • The results of the study showed Theranos' test results were 160% more likely to be abnormal. The specific analyte cited was cholesterol, which Theranos showed a systematic bias toward lower values. Researchers said the variance was large enough to exceed the regulatory limit which could lead to inappropriate choices by doctors and patients based on inaccurate data.
    • Unsurprisingly, the company takes a dim view of the study saying, "We do not believe that the actions of the authors present a sound or scientific way to engage with us about the efficacy of our technologies. It has produced a flawed and inaccurate study and we are disappointed that any journal would accept this study for publication."
    • Theranos' claim to fame is the premise that its tests can be performed on a few drops of blood collected in its "nanotainer" on its proprietary analyzers with comparable results to traditional methods. The company has struggled getting its mysterious technology on line, however.  It has stopped using its nanotainers for all but one of its 260 available tests and is allegedly performing most of its analyses on commercially available equipment.
    • Previously: Theranos risks losing largest customer over quality problems (Feb. 11)
    | Mon, Mar. 28, 5:39 PM | 1 Comment
  • Thu, Jan. 28, 10:50 AM
    • Quest Diagnostics (DGX -2.4%) Q4 results: Revenues: $1,849M (-1.8%); SG&A: $429M (+0.5%); Operating Income: $239M (-7.0%); Net Income: $188M (+1.6%); EPS: $1.29 (+2.4%); Non-GAAP EPS: $1.19 (+0.8%).
    • FY2015 results: Revenues: $7,493M (+0.8%); SG&A: $1,679M (-2.8%); Operating Income: $1,399M (+42.3%); Net Income: $709M (+28.7%); EPS: $4.87 (+28.8%); Non-GAAP EPS: $4.77 (+6.0%); Quick Assets: $133M (-30.7%).
    • 2016 Guidance: Revenue: $7.52B - 7.59B; non-GAAP EPS: $5.02 - 5.17; CF Ops: ~$1B; CAPEX: $250M - 300M.
    | Thu, Jan. 28, 10:50 AM
Company Description
Quest Diagnostics, Inc. is engaged in providing diagnostic testing, information and services that help patients, physicians and others to make better healthcare decisions. The company operates through two segments: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic... More
Sector: Healthcare
Industry: Medical Laboratories & Research
Country: United States